

Supplementary Results

From our complete clinical database of newly seen patients at our institution between 2016-2020, 35 patients were not included in the study. Of these, 27 were transfers from referring institutions mid treatment such that diagnostic pathology material from initial diagnosis were not available, 3 did not have genetic testing performed on their diagnostic samples (insufficient material), and 1 patient was transferred out before having any diagnostic workup. The remaining 4 patients did have genetic testing but were not included in this study because they transferred to other institutions in the midst of therapy, and follow-up information was not available.

Among the 273 patients in the study cohort, 82 patients were enrolled on ongoing Children's Oncology Group (COG) studies. 189 patients were treated on standard-of-care regimens based on prior COG studies. These included COG studies AALL0932, AALL0232, and AALL1131.

Among the 8 patients with BCR::ABL1-rearranged (Ph+) B-ALL, 7 were additionally treated with dasatinib and 1 with imatinib. One infant patient was treated on an infant-specific regimen. One patient died before the initiation of therapy.